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ARTICLE
De novo biosynthesis of bioactive isoflavonoids
by engineered yeast cell factories
Quanli Liu1,2,7, Yi Liu1,2,7, Gang Li1,2, Otto Savolainen1,3,4, Yun Chen 1,2 & Jens Nielsen 1,2,5,6✉
Isoflavonoids comprise a class of plant natural products with great nutraceutical, pharmaceutical
and agricultural significance. Their low abundance in nature and structural complexity however
hampers access to these phytochemicals through traditional crop-based manufacturing or
chemical synthesis. Microbial bioproduction therefore represents an attractive alternative. Here,
we engineer the metabolism of Saccharomyces cerevisiae to become a platform for efficient
production of daidzein, a core chemical scaffold for isoflavonoid biosynthesis, and demonstrate
its application towards producing bioactive glucosides from glucose, following the
screening-reconstruction-application engineering framework. First, we rebuild daidzein
biosynthesis in yeast and its production is then improved by 94-fold through screening
biosynthetic enzymes, identifying rate-limiting steps, implementing dynamic control,
engineering substrate trafficking and fine-tuning competing metabolic processes. The
optimized strain produces up to 85.4 mg L−1 of daidzein and introducing plant glycosyl-
transferases in this strain results in production of bioactive puerarin (72.8 mg L−1) and
daidzin (73.2 mg L−1). Our work provides a promising step towards developing synthetic
yeast cell factories for de novo biosynthesis of value-added isoflavonoids and the multi-
phased framework may be extended to engineer pathways of complex natural products in
other microbial hosts.
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Isoflavonoids constitute a diverse family of natural productsthat are primarily synthesized by leguminous plants1. Inaddition to playing significant ecological functions2, iso-
flavonoids exhibit various human health-promoting properties,
such as antioxidant activity, cardioprotective activity, osteo-
porosis reduction, and cancer prevention, all of which have
resulted in studies on exploiting these molecules as agents both in
the pharmaceutical and nutraceutical industry3,4. The current
production of isoflavonoids relies on direct plant extraction.
However, the low phytochemical abundance, significant invest-
ment of time, energy, and capital, and huge requirement for
potentially toxic solvents have excluded this approach from being
used as it is neither economical nor environmental-friendly5,6.
Moreover, the cultivation of legumes is geographically uneven
and the amounts of isoflavonoids vary greatly from cultivars and
climatic conditions7. All these facts introduce further risk and
instability in the supply of these chemicals by means of plant
extraction. Developing alternative sources of isoflavonoids is
therefore a prominent challenge to be addressed, prior to being
able to feasibly produce these chemicals at scale using standar-
dized industrial processes.
With the rapid advance in metabolic engineering and synthetic
biology over the last few decades, microbe-based bioproduction
has become increasingly pursued as an alternative to traditional
chemical production techniques8,9. By re-engineering the cellular
metabolism of fast-growing microorganisms, such as Escherichia
coli and Saccharomyces cerevisiae, artificial cell platforms have
been successfully constructed to produce high levels of chemicals
ranging from biofuels to proteins10. In addition, grafting and
optimizing plant biosynthetic pathways in microbial hosts is
becoming a compelling route to supply plant natural products, as
demonstrated by substantial biosynthesis of high-value-added
alkaloids, stilbenes, and flavonoids, and terpenoids from simple
sugar11–15. Based on this growing body of work, we speculated
that microbial cell factories may also offer the potential for the
production of commercially viable isoflavonoid as well.
Structurally, isoflavonoids contain the common C6-C3-C6
flavonoid skeleton and are characterized by having the B-ring
connected at C3 rather than C2 position of the C-ring, com-
pared to other flavonoid subclasses3 (Supplementary Fig. 1). The
isoflavones genistein (GEIN) and daidzein (DEIN) constitute
two basic scaffolds from which over thousands of isoflavonoids
are derived as a result of diverse structural modifications,
including hydroxylation, methylation, glycosylation, and mole-
cular rearrangements2–4. Reconstruction of the isoflavone
pathway for biosynthesis of these molecules, therefore, repre-
sents the entry point to microbial production of a large variety
of different biologically active isoflavonoids. Previously, het-
erologous biosynthesis of GEIN and DEIN was demonstrated
by introducing plant enzymes alongside feeding precursors, such
as L-tyrosine, naringenin, or liquiritigenin, in both E. coli and
S. cerevisiae16–21. Moreover, the expression of specific gluco-
syltransferase in E. coli also enabled the bioconversion of GEIN
and DEIN to corresponding glucosides genistin (GIN) and
daidzin (DIN)22,23, the primary form of stored isoflavones in
leguminous plants3. While the reported low titers necessitate
further improvement to support industrial-scale production,
there have been rare efforts to engineer and optimize de novo
microbial biosynthesis of isoflavones.
Here we present the establishment of a de novo DEIN-
producing yeast platform and its application for the biosynth-
esis of glycosylated isoflavonoids using a multi-phased meta-
bolic engineering strategy (Fig. 1). In screening phase I, we first
evaluated diverse plant enzymes to rebuild a functional DEIN
pathway and extensively diagnosed exogenous and endogenous
metabolic factors affecting the activity of key biosynthetic
enzymes. Through pathway reconstruction in phase II, we
improved the metabolic flux towards the DEIN pathway by
implementing: (1) gene amplification to promote the expression
of selected pathway genes; (2) protein fusion strategy to facil-
itate substrate trafficking; (3) additional genetic manipulations
to increase the supply of metabolic cofactors (identified during
phase I to be potential bottlenecks in pathway flux); (4) process
development; and (5) fine-tuning of gene expression in the
competing metabolic pathways. The systematic engineering
enabled the production of 85.4 mg L−1 DEIN from glucose in
shake flask cultivations. Finally, during application phase III,
we demonstrated the efficient conversion of DEIN to bioactive
glycosylated isoflavonoids by introducing plant glycosyl-
transferases. Supplementary Fig. 2 provides an overview of all
strains constructed in the different phases of the development
process.
Results
Phase I—Establishing the biosynthesis of scaffold isoflavone
DEIN. In plants, the general phenylpropanoid pathway uses the
aromatic amino acid (AAA) L-phenylalanine as a precursor for
the biosynthesis of isoflavonoids as well as other flavonoids24.
The initial steps engage phenylalanine ammonia lyase (PAL),
cinnamic acid 4-hydroxylase (C4H), and 4-coumarate-coenzyme
A ligase (4CL), resulting in the conversion of L-phenylalanine to
p-coumaroyl thioester. Subsequently, the chalcone precursors,
naringenin chalcone (NCO) and deoxychalcone isoliquiritigenin
(ISOLIG), are synthesized from the condensation of p-coumaroyl
CoA and three molecules of malonyl-CoA by chalcone synthase
(CHS) alone or with the co-action of NADPH-dependent
chalcone reductase (CHR), respectively25. Chalcone isomerase
(CHI) is responsible for the further isomerization of chalcone to
flavanone26. While naringenin (NAG) acts as the shared struc-
tural core in isoflavone GEIN and flavonoids pathways, the
flavanone liquiritigenin (LIG) is used for the biosynthesis of
isoflavone DEIN. The efficient generation of LIG represents
therefore the first step towards developing a yeast platform for
producing DEIN.
To facilitate the screening of biosynthetic enzymes for LIG
production, we used a yeast platform strain (QL11) that has
previously been reported to produce a moderate level of
p-coumaric acid (p-HCA) (exceeding 300 mg L−1) from glucose
without notable growth deficit27. The plant candidate genes have
been selected according to their source and enzymatic specificity/
activity. We first evaluated the combinations of candidate CHS,
CHR, and CHI homologs, alongside the well-characterized
At4CL1 from Arabidopsis thaliana, for the biosynthesis of LIG
(Fig. 2a). Specifically, three CHS-coding genes, including
leguminous GmCHS8 (Glycine max) and PlCHS (Pueraria lobate)
as well as non-leguminous RsCHS (Rhododendron simsii), were
selected (Supplementary Fig. 3a). CHR activity has been mostly
demonstrated in leguminous species28; thus GmCHR5, PlCHR,
and MsCHR (Medicago sativa) were screened (Supplementary
Fig. 3a). Plant CHIs can be categorized into distinct isoform
groups according to their evolutionary path and enzymatic
profiles. Whereas type I CHIs, common to all vascular plants,
convert only NCO to NAG, legume-specific type II CHIs are
capable of yielding both NAG and LIG26. Correspondingly, type
II CHI-coding genes PlCHI1 and GmCHI1B2 were evaluated,
together with a type I CHI-coding gene PsCHI1 (Paeonia
suffruticosa) being used as a control for enzymatic activity. All
biosynthetic genes were chromosomally integrated and tran-
scriptionally controlled by strong constitutive promoters. Co-
overexpression of At4CL1, GmCHR5, GmCHS8, and GmCHI1B2
resulted in the best LIG production at a level of 9.8 mg L−1 (strain
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C09) among all resultant strains (C01−C11, Fig. 2b). In addition,
strains C01, C04−05 and C10 generated no detectable amounts of
isoflavonoid intermediates, which could be attributed to the
narrow substrate specificity of type I PsCHI1 (strain C01) and low
enzymatic activity of PlCHR in yeast (strains C04-05 and C10),
respectively (Fig. 2b and Supplementary Fig. 3b). Subsequently,
individual gene replacement in strain C09 allowed the efficient
screening of additional 4CL, CHS, and CHI variants. Five plant
4CL-coding genes, including Pl4CL1, Gm4CL3, At4CL2, Ph4CL1
(Petunia hybrida), Pc4CL2 (Petroselinum crispum) and a mutant
At4CL1m (I250L, N404K, I461V)29, were overexpressed to
generate LIG (strains C12−C17) (Supplementary Fig. 3a);
however, none of these genes outperformed the wild-type At4CL1
(C09) (Fig. 2c). Also, no improvement on LIG production was
observed for strains expressing alternative variants of CHS
(strains C18−C20) or CHI (strains C21−C22) (Fig. 2c and
Supplementary Fig. 3c). Strain C09 was therefore chosen as the
















































































































































Fig. 1 Engineering the de novo biosynthesis of isoflavonoid chemicals in yeast. A multi-phased metabolic engineering strategy was implemented to
enable de novo production of isoflavonoids, following the pipeline of screening-reconstruction-application. In screening phase I (green box), a synthetic
DEIN pathway was established and metabolic factors improving the performance of rate-limiting reactions were identified using a moderate p-HCA
producing platform strain QL11. In reconstruction phase II (orange box), the DEIN production was further optimized in a wild-type strain QL179 harboring
the deletion of galactose utilizing genes (GAL7/10/1), through amplifying gene expression, enhancing substrate transfer, combining effective genetic
targets identified in phase I and fine-tuning the expression of a key gene involved in competing metabolic pathway (orange triangle). For application phase
III (magenta box), the generated DEIN platform strain was used as the starting point for the production of bioactive glucosides PIN and DIN through
introducing plant glycosyltransferases and enhancing the supply of glycosyl group donor UDP-glucose. The selected plant biosynthetic genes and
overexpressed yeast native genes for isoflavonoid production were highlighted in blue boxes. Magenta arrows, designed DEIN biosynthetic pathway. Blue
arrows, reactions for generating glucosides; gray arrows, byproduct pathway. At4CL1, 4-coumarate-coenzyme A ligase 1 from Arabidopsis thaliana; GmCHS8,
chalcone synthase from Glycine max; GmCHR5, chalcone reductase from G. max; GmCHIB2, chalcone isomerase from G. max; Ge2-HIS,
2-hydroxyisoflavanone synthase from Glycyrrhiza echinata; GmHID, 2-hydroxyisoflavanone dehydratase from G. max; AtPAL2, phenylalanine ammonia lyase
from A. thaliana; AtC4H, cinnamic acid-4-hydroxylase from A. thaliana; FAS1, beta subunit of yeast fatty acid synthetase; CrCPR2, cytochrome P450
reductase from Catharanthus roseus; STB5, yeast native transcriptional factor; EcyjfB, NAD+ kinase from Escherichia coli; GmUGT4, isoflavone 7-O-
glucosyltransferase from G. max; PlUGT43, isoflavone 8-C-glucosyltransferase from Pueraria lobate; UGP1, UDP-glucose pyrophosphorylase; PGM1/2,
phosphoglucomutase 1/2. In addition, yeast heme degradation was disrupted by deleting heme oxygenase-coding gene HMX1. ER endoplasmic reticulum,
E4P erythrose-4-phosphate, PEP phosphoenolpyruvate, L-Phe L-phenylalanine, 5-ALA 5-aminolevulinic acid, UDP-Glc uridine diphosphate-glucose, UTP
uridine triphosphate, G-6-P glucose-6-phosphate, G-1-P glucose-1-phosphate.
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The entry point enzyme in the isoflavonoid biosynthetic
pathway is 2-hydroxyisoflavanone synthase (2-HIS), which
belongs to the cytochrome P450 family and catalyzes the
intramolecular aryl migration of the B-ring yielding the
intermediate 2-hydroxyisoflavanones25. Subsequently, dehydra-
tion of the resultant intermediate products, catalyzed by
2-hydroxyisoflavanone dehydratase (HID), gives rise to corre-
sponding isoflavones30 (Fig. 2a). The 2-HIS and HID-coding
genes were mainly identified in legumes that have been confirmed
to produce isoflavonoids25. To identify efficient biosynthetic
enzymes for DEIN formation, a group of leguminous 2-HIS and
HID homologs were screened. Specifically, five 2-HIS-coding
genes, including Pl2-HIS, Gm2-HIS1, Mt2-HIS1 (Medicago
truncatula), Tp2-HIS (Trifolium pretense), and Ge2-HIS (Glycyr-
rhiza echinata), and three HID-coding genes, including PlHID,
GmHID, and GeHID, were combined and overexpressed in strain
C09 (Fig. 2d). While most engineered strains generated detectable
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Fig. 2 Building and validating the biosynthetic pathway for DEIN. a Schematic illustration of the biosynthetic pathways leading to the production of DEIN
and related byproducts. To ensure efficient screening of biosynthetic enzymes for DEIN production, a p-HCA producing strain QL11, harboring
overexpression of enzymes responsible for both endogenous (yellow arrows) and exogenous (blue arrows) reactions, was selected as the starting strain.
ARO3, DAHP synthase; ARO4*, L-tyrosine-feedback-insensitive DAHP synthase (ARO4K229L); ARO1, pentafunctional aromatic protein; EcaroL, shikimate
kinase from E. coli; ARO2, chorismate synthase; ARO7*, L-tyrosine-feedback-insensitive chorismate mutase (ARO7G141S); AtATR2, cytochrome P450
reductase from A. thaliana; CYB5, yeast native cytochrome b5. DAHP, 3-deoxy-D-arabino-2-heptulosonic acid 7-phosphate; SHIK, shikimate; S3P,
shikimate-3-phosphate; EPSP, 5-enolpyruvyl-shikimate-3-phosphate; CHA, chorismic acid; PPA, prephenate. See Fig. 1 and its legend regarding
abbreviations of metabolites and other gene details. b, c Production profiles of intermediates LIG and ISOLIG produced by yeast strains harboring different
combinations of biosynthetic enzymes 4CL, CHS, CHR, and CHI. d DEIN production of C09 strain overexpressing different biosynthetic genes encoding
2-HIS and HID and relevant genetic characteristics of the resultant strains. For the source of selected plant genes: Mt, Medicago truncatula; Tp, Trifolium
pretense. See Fig. 1 legend regarding abbreviations of other plant species. Cells were grown in a defined minimal medium with 30 g L−1 glucose as the sole
carbon source, and cultures were sampled after 72 h of growth for metabolite detection. All data represent the mean of n= 3 biologically independent
samples and error bars show standard deviation. The source data underlying figures (b−d) are provided in a Source Data file.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-26361-1
4 NATURE COMMUNICATIONS |         (2021) 12:6085 | https://doi.org/10.1038/s41467-021-26361-1 | www.nature.com/naturecommunications
Ge2-HIS and GmHID, accumulated the highest level of DEIN to
0.9 mg L−1 (Fig. 2d). These results show the feasibility to build de
novo biosynthesis of DEIN in yeast by harnessing the diversity of
plant pathway enzymes.
Phase I—Engineering the redox partner of the key enzyme
P450 2-HIS. Though strain C28 produced DEIN, only a low titer
was obtained with a concomitant buildup of the biosynthetic
intermediate LIG (Supplementary Fig. 4), suggesting inefficiencies
in product formation in the later stage of the DEIN pathway. We,
therefore, moved on to engineering the activity of Ge2-HIS,
considering that the P450-mediated reactions are irreversible and
often rate-limiting31 whereas HID is believed to facilitate the
spontaneous dehydration of 2-hydroxyisoflavanones16,30.
The redox partner (RP) is an integral part of canonical
P450 systems that shuttles the electrons derived from NAD(P)H
to the heme iron-center to enable oxygen cleavage and substrate
monooxygenation32. The endoplasmic reticulum (ER)-anchored
plant P450s recruit a single RP protein, the membrane-attached
flavin adenine dinucleotide (FAD)/flavin mononucleotide
(FMN)-containing cytochrome P450 reductase (CPR), to transfer
electrons33 (Fig. 3a). Co-expression of the cognate CPRs is a
common practice for reconstituting P450-involved plant biosyn-
thetic pathways in yeast, such as the production of terpenoid12
and alkaloid11, which has been believed to permit more efficient
P450-CPR coupling compared to the native yeast CPR33. In
addition, plant CPRs exhibit a certain degree of versatility, due to
the high level of conservation represented by the amino acid
residues that mediate P450 interactions33. Accordingly, in our
DEIN-producing strains, Ge2-HIS might receive electrons from
AtATR2, a CPR homolog of A. thaliana introduced for
optimizing the activity of P450 AtC4H to produce p-HCA
(Fig. 3a). However, the limiting Ge2-HIS activity evidenced by a
low DEIN titer of strain C28 motivated us to exploit alternative
plant CPRs, including GmCPR1 and CrCPR2 (Catharanthus
roseus) (Fig. 3b). The selected CPR-coding genes were chromo-
somally integrated in combination with a second copy of Ge2-HIS
to strain C28. Using this approach, DEIN production of both
GmCRP1-expressing strain C34 and CrCRP2-expressing strain
C35 was significantly enhanced to a titer of 5.9 and 9.9 mg L−1,
respectively, accounting for a 284 and 544% increase compared
with that of strain C33 only harboring a second copy of Ge2-HIS
(Fig. 3c). This strongly indicates that there may be an improved
coupling of the alternative CPRs to Ge2-HIS.
Among the diverse range of P450-dependent electron transport
systems, an intramolecular electron transfer mechanism has been
employed by the so-called self-sufficient P450s, in which the RP
domain is naturally fused with the catalytic domain32. This
unique group of P450s exhibit many advantages, including higher
electron transfer efficiency, improved substrate turnover, as well
as no need for a separate RP, and therefore are of great interest
for biotechnological applications34. To mimic this intramolecular
electron transfer, surrogate RPs derived from prominent self-
sufficient bacterial P450s, including (1) BM3R, the eukaryotic-
like reductase domain of P450BM3 from Bacillus megaterium35;
































































































































Fig. 3 Tailoring the redox partner of Ge2-HIS for efficient DEIN production. a Schematic illustration of the biosynthetic pathways leading to the
production of DEIN and related byproducts. P450 enzymes are indicated in magenta. In addition, a general catalytic mechanism of the membrane-bound
plant P450 is shown in the inset. See Fig. 1 and its legend regarding abbreviations of metabolites and gene details. b Different redox partners (RPs)
including CPR and surrogate redox partners from self-sufficient P450s were tested to enhance the catalytic activity of P450 Ge2-HIS. GmCPR1, cytochrome
P450 reductase from G. max; BM3R, the eukaryotic-like reductase domain of P450BM3 from Bacillus megaterium; RhFRED, the FMN/Fe2S2-containing
reductase domain of P450RhF from Rhodococcus sp. strain NCIMB 9784; RhF-fdx, a hybrid reductase by substituting Fe2S2 domain of RhFRED with
ferredoxin (Fdx) from spinach. See Fig. 1 and its legend regarding abbreviations of metabolites and other gene details. c Effect of different RPs on the
production of DEIN. Cells were grown in a defined minimal medium with 30 g L−1 glucose as the sole carbon source, and cultures were sampled after 72 h
of growth for metabolite detection. Statistical analysis was performed by using Student’s t test (two-tailed; two-sample unequal variance; *p < 0.05,
**p < 0.01, ***p < 0.001). All data represent the mean of n= 3 biologically independent samples and error bars show standard deviation. The source data
underlying panel (c) are provided in a Source Data file.
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P450RhF from Rhodococcus sp. strain NCIMB 978436; and (3)
RhF-fdx, a hybrid reductase by substituting Fe2S2 domain of
RhFRED with ferredoxin (Fdx) from spinach37, were
C-terminally fused to Ge2-HIS and investigated for DEIN
production (Fig. 3b). These chimeras were co-expressed with an
additional copy of Ge2-HIS. While strain C36 harboring Ge2-
HIS/BM3R fusion had a 156% increase in DEIN production,
compared with the control strain C33 (Fig. 3c), the introduction
of RhFRED and RhF-fdx decreased the biosynthesis of DEIN of
corresponding engineered strains C37 and C38 (Fig. 3c).
Phase I—Identifying potential metabolic factors improving
2-HIS activity. Besides pairing with an appropriate RP, the
attainment of high P450 catalytic efficiency is challenged by (I)
the intracellular level of heme for the assembly of holoenzymes,
(II) the ER microenvironment to accommodate functional
membrane proteins and (III) the availability of redox cofactors.
Next, we moved to uncover potential bottlenecks regarding these
factors in limiting the biosynthesis of DEIN (Fig. 4a).
The production of active P450s requires sufficient incorpora-
tion of cofactor heme, which may deplete the intracellular pool of
heme and thereby incur a cellular stress response that in turn
damages the net enzymatic activity38. To mitigate this potential
adverse effect on the activity of Ge2-HIS, we tested different
approaches to regulate heme metabolism of yeast (Fig. 4a-I). Co-
overexpression of two rate-limiting enzymes in yeast heme
biosynthesis, encoded by genes HEM2 and HEM339, slightly
enhanced the production of DEIN to 9.5 mg L−1 (strain C39,
Fig. 4b). In addition, a previous study illustrated that inactivation
of the transcriptional repressor Rox1 could render an elevated
cellular heme level40, resulting from the derepression of the heme
biosynthetic gene HEM13. We, therefore, deleted ROX1 in strain
C35, yielding a DEIN titer of 12.8 mg L−1 by the resultant strain
C40 (Fig. 4b), a 46% increase compared with that of the parental
strain. Besides reinforcing the biosynthetic pathway, reducing
degradation of heme also contributes to its intracellular
accumulation and improves the P450s activity41. Accordingly,
upon the deletion of HMX1, which encodes heme oxygenase





































Core reaction for 2-HIS
Titer (mg L-1)



























































 NDP + NADPH
YEF1
NAD++ NTP
 NDP + NADP+
EcyfjB
(M1) Dehydrogenase-dependent (M2) Transhydrogenase-dependent




















































Fig. 4 Investigation of metabolic factors affecting DEIN biosynthesis. a Schematic illustration of the genetic modifications performed to relieve potential
metabolic limitations, regarding heme metabolism (I), ER homeostasis (II), and cofactor NADPH generation (III), to improve the performance of P450 Ge2-
HIS. Overexpressed genes are shown in bold and gene deletion is marked with a red cross. Red circle and arrows, transcriptional factors (TFs) activating a
metabolic gene/pathway; Blue circle and flat-head arrow, TFs repressing a metabolic gene/pathway. HEM2, 5-aminolevulinic acid dehydratase; HEM3,
4-porphobilinogen deaminase; HEM13, coproporphyrinogen III oxidase; ROX1, heme-dependent repressor of hypoxic genes; PAH1, phosphatidate
phosphatase; INO2/OPI1, transcription activator/repressor of phospholipid biosynthetic genes; ALD6, cytoplasmic NADP+-dependent aldehyde
dehydrogenase; EcpntAB, membrane-bound transhydrogenase from E. coli; YEF1, ATP-NADH kinase. Suc-CoA, succinyl-CoA; PA, phosphatidic acid; PL,
phospholipid; DAG, diacylglycerol; X-5-P, xylulose-5-phosphate; AcD, acetaldehyde; Ac, acetate; NTP, nucleoside triphosphates; NDP, nucleoside
diphosphates. See Fig. 1 and its legend regarding abbreviations of metabolites and other gene details. Production of DEIN by engineered yeast strains
derived from strategy groups I (b), II (c), and III (d), respectively. Cells were grown in a defined minimal medium with 30 g L−1 glucose as the sole carbon
source, and cultures were sampled after 72 h of growth for metabolite analysis. Statistical analysis was performed by using Student’s t test (two-tailed;
two-sample unequal variance; *p < 0.05, **p < 0.01, ***p < 0.001). All data represent the mean of n= 3 biologically independent samples and error bars
show standard deviation. The source data underlying panels (b−d) are provided in a Source Data file.
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resultant strain C41 (10.6 mg L−1) was increased by 21% relative
to strain C35 (Fig. 4b).
Most plant-derived P450s and CPRs are independently
tethered onto the ER via hydrophobic transmembrane
anchors42. Modulating the biogenesis and size of the ER has
previously been shown to enhance P450-involved biosynthesis
of terpenoids in S. cerevisiae43,44, a result which is likely due to
a higher protein folding capacity enabled by ER expansion. To
evaluate the possible beneficial effect of ER expansion for DEIN
biosynthesis, we therefore elevated the intracellular level of
phospholipids for ER assembly by implementing (1) the
deletion of PAH1-encoded phosphatidate phosphatase that
competes for the phospholipid precursor45,46; (2) the deletion
of the transcription factor Opi1 and (3) overexpression of the
transcription factor Ino2 that negatively and positively control
the expression of UASINO-containing phospholipid biosyn-
thetic genes, respectively47 (Fig. 4a-II). A significantly enhanced
DEIN generation was observed for the OPI1 deletion strain
C43 (10.8 mg L−1) and the INO2-overexpressing strain C44
(11.3 mg L−1), representing a 20 and 26% increase relative to
strain C35 (Fig. 4c). Moreover, strain C46 harboring PAH1
deletion and INO2 overexpression also had a 20% increase in
DEIN formation (10.8 mg L−1) compared with that of strain
C35, whereas other combinatorial modifications led to a
reduction in DEIN titers of strains C45 and C47 (Fig. 4c). This
difference could be attributed to the remarkably impaired cell
growth of the latter two strains (Supplementary Fig. 5).
Redox cofactors NAD(P)H, the ultimate electron source in
cellular metabolism, are indispensable for the catalytic cycle of
plant P450s33. Lack of NAD(P)H could reduce the P450 activity
due to inefficient electron transfer. A recent report indicated
that improved cellular NADPH level could enhance the P450-
mediated protopanaxadiol production48. Thus, we decided to
reroute the redox metabolism to fuel the activity of Ge2-HIS. In
the first strategy, genetic modifications engaged to boost the
direct generation of NADPH were devised and individually
implemented, including (M1a) overexpression of the transcrip-
tional factor Stb5 that activates the expression of genes involved
in the pentose phosphate pathway (PPP)49, the major source of
NADPH for anabolic processes in yeast; (M1b) overexpression
of the ALD6-encoded cytoplasmic NADP+-dependent aldehyde
dehydrogenase that converts acetaldehyde to acetate; (M2)
introduction of E. coli pntAB genes encoding a membrane-
bound transhydrogenase capable of reducing NADP+ at the
expense of NADH50; and (M3) overexpression of yeast YEF1-
encoded ATP-NADH kinase that directly phosphorylates
NADH to NADPH51, resulting in an elevated concentration
of the phosphorylated form of this cofactor without impact on
the NADPH/NAPD+ ratio (Fig. 4a-III). The resultant strains
C49 (M1b) and C51 (M3) produced 9.9 and 9.7 mg L−1 of
DEIN, representing a 14% and 11% increase, respectively,
compared with the parental strain C35 (Fig. 4d). Moreover,
combined overexpression of NAD+ kinase (NADK), the sole
enzyme leading to de novo NADP+ biosynthesis, with an
NADP+ reducing enzyme was shown to improve NADPH-
consumed bacterial isobutanol production52. We, therefore,
evaluated this strategy via further co-expressing a prokaryotic
NADK-coding gene EcyfjB (M4) (Fig. 4a-III). The reported
synergistic effect was most evident for strain C52, containing
(M1a) and (M4), which had a 17% increase in DEIN titer
relative to strain C48 (Fig. 4d).
Phase II—Gene amplification and engineering of substrate
trafficking improve DEIN biosynthesis. In screening phase I,
through performing combinatorial gene screening in parallel with
multiple genetic modifications, we achieved substantial de novo
DEIN biosynthesis and identified important metabolic factors
affecting its overproduction in yeast. However, the resultant
strains exhibited two major unfavorable phenotypes, including a
large amount of non-consumed precursor p-HCA (Supplemen-
tary Fig. 6) and the formation of several metabolic intermediates
and byproducts (Supplementary Fig. 7). This may result from (1)
metabolic imbalance between upstream p-HCA producing
and the downstream pathways, (2) insufficient activity and (3)
substrate promiscuity of some of the plant enzymes, and (4)
inefficient cytosolic substrate transfer. We therefore next aimed to
improve the production of DEIN via relieving these potential
metabolic barriers.
To reduce the metabolic loss due to an excessive supply of p-HCA
in background strain QL11, we instead turned to reconstructing the
DEIN biosynthesis in a “clean” background without an engineered
AAA pathway. With this strain, we used the galactose-induced
dynamic transcription mechanism53, which is mediated by GAL
promoters (GALps) and has been successfully used for high-level
production of value-added chemicals12,27, to enhance the expression
of DEIN pathway genes. A previously described strain QL17927,
derived from IMX581 by disrupting galactose utilization genes
GAL1/10/7, was thus selected to confer galactose as the gratuitous
inducer to activate GALps (Fig. 5a). As expected, simultaneous
introduction of the GALps-controlled p-HCA and LIG pathways
greatly boosted LIG titer to 37.6mg L−1 in strain I01 (Fig. 5b), a
284% increase relative to strain C09, in which a constitutive gene
expression pattern was used. Interestingly, a markedly low level of p-
HCA was detected in strain I01, indicating that to a certain extent the
metabolic flux between the redesigned p-HCA producing and
consuming pathways was balanced (Supplementary Fig. 8).
The spatial organization of catalytic enzymes is increasingly
recognized to be critical for optimizing the metabolic flow
through multi-step biosynthetic pathways54. Coordinating the
physical distance of adjacent enzymes, mediated by peptide
linkers or synthetic scaffolds, could elevate local concentrations of
enzymes and metabolites thereby speeding up the turnover of
intermediates, minimizing metabolic crosstalk, and improving
reaction flux55. To test this, we implemented a synthetic fusion
enzyme strategy to optimize the substrate trafficking through the
LIG pathway. Specifically, two distinct oligopeptide linkers
possessing flexible (GGGS, L1) or rigid (VDEAAAKSGR, L2)
conformations56 were applied to fuse the coding sequences of
neighboring enzymes (Fig. 5a). Fused AtC4H (E1) with At4CL1
(E2) in both tandem orientations together with other biosynthetic
genes were chromosomally integrated into strain QL179, creating
strains I02−I05 (Fig. 5b). A significantly enhanced LIG produc-
tion was observed for these strains; and fusion enzyme in the E1-
L1-E2 orientation provided the highest LIG titer of 77.7 mg L−1
(strain I02), representing a 107% improvement compared with
strain I01 (Fig. 5b). This result indicates that the physical fusion
of two enzymes responsible for the formation and consumption
of p-HCA, respectively, could greatly drive the metabolic flux
towards LIG biosynthesis. Encouraged by this, we further
introduced fusion enzymes consisting of GmCHS8 (E3)-Linker-
GmCHR5 (E4) or GmCHR5 (E4)-Linker-GmCHI1B2 (E5) to
strain I02 (Fig. 5a). In contrast, here we found the titer of LIG to
be decreased in the resultant strains I06-I13 (Supplementary
Fig. 9), which may be attributed to a reduced CHR activity of
fusion enzymes, considering the lower variation we observed for
byproduct formation. We, therefore, selected strain I02 as the
platform for incorporating the best downstream DEIN-forming
biosynthetic and auxiliary enzymes (Ge2-HIS, GmHID, and
CrCPR2). The DEIN titer of resultant strain I14 (20.7 mg L−1,
Fig. 5c) doubled relative to strain C35 harboring the constitutive
promoter-driven DEIN pathway (9.9 mg L−1, Fig. 3c).
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Phase II—Combinatorial strategies to increase DEIN production.
Improving the expression of biosynthetic genes and the cellular
substrate transfer greatly enhanced the DEIN titer of strain I14.
However, we also observed considerable accumulation of both
intermediates (15.8mg L−1 of ISOLIG and 42.3mg L−1 of LIG,
Fig. 5c) as well as byproducts (10.0mg L−1 of NAG and 1.3mg L−1
of GEIN, Fig. 5c), showing a need for strengthening the later stage of
DEIN biosynthesis. To solve this, we first aimed to improve the
activity of Ge2-HIS by combining effective P450-centered genetic
targets identified in phase I engineering (Fig. 4a). Expectedly, the
removal of heme degradation by disrupting HMX1 gene resulted in a
19% increase in DEIN titer of strain I15 (23.3mg L−1) compared
with that of strain I14 (Fig. 6a), whereas ROX1 deletion negatively
affected DEIN production (strain I16, Fig. 6a), this potentially being
caused by the resulting loss of its regulatory role in stress resistance of
S. cerevisiae40. Subsequently, the deletion of OPI1 or overexpression
of INO2 genes was individually carried out to stimulate ER expansion
in strain I15; however, both resultant strains gave a lower DEIN titer
(Supplementary Fig. 10a). While compromised cell growth associated
with these strains (Supplementary Fig. 10b) could have weakened
their DEIN generation, a shortage of intracellular heme may also
be limiting the functional P450 folding and thereby blunting
the effect of ER adjustment. Previous studies showed that feeding
5-aminolevulinic acid (5-ALA), the direct precursor of heme bio-
synthesis, could significantly increase the cellular heme level of
yeast38. Indeed, we found exogenous supplementation of 1mM
5-ALA resulted in 45% (34.3mg L−1, strain I15+A), 65%
(17.3mg L−1, strain I17+A), and 42% (27.1mg L−1, strain
I18+A), respectively, further increases in DEIN production for the
strains tested (Fig. 6b and Supplementary Fig. 10a). ER-targeting
modifications however exhibited no beneficial effects on DEIN pro-
duction, which could be ascribed to the distinct engineering context
of strains C35 and I15, implying a need for fine-tuning the interplay
between ER biogenesis and P450 anchoring. Thus, strain I15 was
subject to the integration of NADPH generation systems. Among
selected targets, co-overexpression of native STB5 and bacterial EcyfjB
genes (M1a+M4) led to the highest DEIN titer of 40.2mg L−1, a
12% improvement relative to strain I15 (strain I21, Supplementary
Fig. 11).
Based on established results of cofactor refinement, we speculated
that the availability of biosynthetic enzymes could emerge as a
limiting factor for the conversion of LIG to DEIN. Especially,
previous reports indicated that the 2-HIS enzyme in microsomal
preparation from soybean cells is labile57 and the catalytic
characteristics of 2-HIS have evolved by sacrificing protein
stability58. We, therefore, introduced extra copies of the best
DEIN-forming gene combination, Ge2-HIS with GmHID, to strain
I21. Interestingly, while there was a 17% increase in DEIN
production in strain I24 containing the second copy of selected
genes, the introduction of the third copy of this gene combination
further enhanced DEIN production to 53.5 mg L−1 (strain I25),
representing a 38% increase compared with strain I21 (Fig. 6c).
Compared with batch (glucose excess) cultivations, yeast cells
grown under glucose-limited cultivation are known to have a
higher biomass yield and an enhanced PPP flux59, the latter being
anticipated to favor AAA biosynthesis by increasing the
availability of the precursor erythrose 4-phosphate. We, therefore,
grew DEIN-producing strains under a mimicked glucose-limited
fed-batch cultivation by using FeedBeads (FB) (Supplementary
Fig. 12), a slow-release system for glucose60. Expectedly, under FB
conditions, strain I25 produced 62.1 mg L−1 of DEIN, represent-
ing an 18% increase relative to the same strain under batch
conditions (Fig. 6d). Moreover, the application of this FB strategy
led to observable growth improvements and a striking increase in
byproduct formation of strain I25 (Supplementary Fig. 13). These
results agree also with our previous work wherein significant
improvements on cellular biomass formation and p-HCA
production could be achieved by growing yeast cells under
glucose-limited conditions27.
For the biosynthesis of one molecule of DEIN, one molecule of
p-coumaroyl-CoA and three molecules of malonyl-CoA are
consumed (Fig. 6e). Following our optimization of metabolic flux
using the p-HCA pathway and reinforcement of the DEIN
biosynthetic pathway, we speculated that the supply of malonyl-
CoA had become the next limiting factor in DEIN production. In
S. cerevisiae, the majority of cytosolic malonyl-CoA pool is
invested in the synthesis of fatty acids (FAs), which are essential
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Fig. 5 Gene amplification and engineering of substrate trafficking improve DEIN production. a Schematic view of the targets and strategies to improve the
substrate transfer along the DEIN biosynthetic pathway. Two different oligopeptide linkers (flexible linker L1, GGGS; rigid linker L2, VDEAAAKSGR) were
employed to fuse the adjacent metabolic enzymes. Strain QL179 was selected to implement GAL promoters (GALps)-mediated gene amplification. See Fig. 1 and
its legend regarding abbreviations of metabolites and other gene details. b Quantification of metabolic intermediates produced by strains carrying a fused
enzyme of AtC4H (E1) and At4CL1 (E2). c Comparison of the production profiles between parental strain I02 and I14 harboring additional overexpression of
selected metabolic enzymes Ge2-HIS and GmHID and auxiliary CrCPR2. Cells were grown in a defined minimal medium with 30 g L−1 glucose as the sole
carbon source and 10 g L−1 galactose as the inducer. Cultures were sampled after 72 h of growth for metabolite detection. Statistical analysis was performed by
using Student’s t test (two-tailed; two-sample unequal variance; *p < 0.05, **p < 0.01, ***p < 0.001). All data represent the mean of n= 3 biologically
independent samples and error bars show standard deviation. The source data underlying panels (b, c) are provided in a Source Data file.
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complex, composed of Fas1 and Fas2, is responsible for FAs
generation in yeast with the FAS1 gene product known to impose
positive autoregulation on FAS2 expression to coordinate the
activity of the FAS complex62. Hence, we set out to fine-tune the
expression of the FAS1 gene to divert malonyl-CoA towards
DEIN biosynthesis (Fig. 6e). A group of yeast promoters,
exhibiting differential transcriptional activities in response to
glucose63 (Supplementary Table 1), were used to substitute the
native FAS1 promoter. Among seven evaluated promoters,
replacement with BGL2p brought about the greatest DEIN titer
of 76.3 mg L−1 (strain I27), a 20% increase compared with strain
I25 (Fig. 6f). Additionally, the production of intermediates and
byproducts was also notably elevated (Supplementary Fig. 14),
further reflecting that promoter replacement of FAS1 has boosted
the overall metabolic flux towards isoflavonoids.
The galactose-induced transcriptional response (the GAL
induction) of S. cerevisiae initiates with the association of the
galactose sensor Gal3 with the regulatory inhibitor Gal80, leading
to dissociation of the latter from the transcription activator Gal4,
thereby allowing rapid expression of GAL genes53. Constitutive
GAL3 mutants (GAL3c) have been demonstrated to confer
galactose-independent activation of Gal4 64. This trait was
recently engineered to build a positive feedback genetic circuit
in which expressed Gal3c provokes greater expression of Gal3c
and thereby enhances GAL induction65. We speculated that
DEIN production may benefit from overexpression of such a
Gal3c mutant as a result of further induction of the GALps-
controlled biosynthetic pathway. However, when expressed from
a high-copy vector under the control of GAL10p, the introduction
of constitutive Gal3S509P mutant led to a significant decrease in
both DEIN and GEIN titers (Fig. 6g and Supplementary Fig. 15).
On the other hand, by deleting gene ELP3, encoding a histone
acetyltransferase that is part of elongator and RNAPII
holoenzyme66, a final DEIN titer of 85.4 mg L−1 was achieved
in the resultant strain I34 (Fig. 6g), representing a 12%
improvement relative to strain I27. The production of GEIN
was also slightly increased to 33.7 mg L−1 (Fig. 6g and
Supplementary Fig. 15). These results also show to be consistent
with a published study wherein ELP3 deletion was found to
enhance the GAL1p-mediated beta-galactosidase activity in the
presence of galactose67. The high-level accumulation of DEIN
could exert cellular toxicity in S. cerevisiae and thereby impede
the further improvement of its titer. We, therefore, evaluated the
growth profiles of the background strain IMX581 under different
concentrations of DEIN within its solubility limit. The results
revealed that yeast could tolerate up to 150mg L−1 of DEIN
without significant loss of growth capacity (Supplementary
Fig. 16). Hence, it is reasonable to assume that the production
of DEIN is non-toxic to yeast at the levels produced here.
Phase III—Production of DEIN-derived glucosides. Glycosyla-
tion represents a prevalent tailoring modification of plant flavo-






















































































































Fig. 6 Combinatorial optimization to increase the production of DEIN. a Effect of deleting genes involved in the regulation of heme metabolism on DEIN
biosynthesis. Production of DEIN by strains fed with the heme biosynthetic precursor 5-ALA (b) or expressing different copies of Ge2-HIS and GmHID
genes (c). d Process optimization for DEIN production. Cells were grown in a defined minimal medium with 30 g L−1 glucose (batch) or with six tablets of
FeedBeads (FB) as the sole carbon source and 10 g L−1 galactose as the inducer. Cultures were sampled after 72 h (batch) or 90 h (FB) of growth for
metabolite analysis. e Schematic view of the interplay between isoflavonoid biosynthesis and yeast cellular metabolism connected by the branchpoint
malonyl-CoA. See Fig. 1 and its legend regarding abbreviations of metabolites and gene details. f Fine-tuning the expression of gene FAS1 via promoter
engineering improves DEIN formation under optimized cultivation conditions. g Effect of genetic modifications altering the regulation of GAL induction on
DEIN production under optimized cultivation conditions. The constitutive mutant of galactose sensor Gal3 (GAL3S509P) was overexpressed from a multi-
copy plasmid (2 µm) under the control of GAL10p and gene ELP3, encoding a histone acetyltransferase, was deleted. Cells were grown in a defined minimal
medium with six tablets of FB as the sole carbon source and 10 g L−1 galactose as the inducer. Cultures were sampled after 90 h of growth for metabolite
detection. Statistical analysis was performed by using Student’s t test (two-tailed; two-sample unequal variance; *p < 0.05, **p < 0.01, ***p < 0.001). All
data represent the mean of n= 3 biologically independent samples and error bars show standard deviation. The source data underlying panels (a−d) and
(f, g) are provided in a Source Data file.
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solubility, stability, and toxicity68. In soybean, enzymatic 7-O-
glucosylation of DEIN leads to the biosynthesis of DIN69, one of
the key ingredients found in soybean-derived functional foods
and nutraceuticals70. Moreover, puerarin (PIN), an 8-C-glucoside
of DEIN, is ascribed as the major bioactive chemical of P. lobate
roots extract, which has long been used in Chinese traditional
medicine for the prevention of cardiovascular diseases71. Recent
studies also show that PIN exhibits diverse pharmacological
properties including antioxidant, anticancer, vasodilation, and
neuroprotection-related activity72. With the establishment of
efficient DEIN-producing yeast platform during reconstruction
phase II (Fig. 6g), we explored its application potential in the
production of PIN and DIN.
The biosynthesis of flavonoid glycosides is mediated by UDP-
sugar-glycosyltransferases (UGTs), which catalyze the formation
of O−C or C−C bond linkages between the glycosyl group from
uridine diphosphate (UDP)-activated donor sugars and the
acceptor molecules1,73. While a soybean isoflavone 7-O-glucosyl-
transferase exhibiting broad substrate scope was first described
over 10 years ago69, only recently Funaki et al.74 revealed that its
homolog GmUGT4 enables highly specific 7-O-glucosylation of
isoflavones. On the other hand, the complete PIN pathway was
fully elucidated when Wang et al.71 successfully cloned and
functionally characterized a P. lobata glucosyltransferase,
encoded by PlUGT43, which displays strict in vitro 8-C-
glucosylation activity towards isoflavones and enables PIN
production in PlUGT43-expressed soybean hairy roots. We,
therefore, tested the feasibility of using these UGTs in generating
DEIN glucosides (Fig. 7a). Different copies of PlUGT43 and
GmUGT4 under the control of constitutive promoters were
integrated into the basic DEIN producer C28, but the resultant
yeast strains (E01−E03 for PIN and E04−E06 for DIN,
Supplementary Fig. 2) generated no detectable level of glycosides
for HPLC analysis. However, through further analysis with high-
resolution LC-MS, we validated that strains E03 and E06 could
generate trace amount of PIN and DIN, respectively (Fig. 7b and
Supplementary Fig. 17), demonstrating that both UGTs were
functional in yeast.
Besides the selection of active UGTs, the supply of glycosyl group
donor UDP-glucose also plays a pivotal role in regulating glucoside
production. With the efficient DEIN producer I34 in hand, we
moved to enhance its capacity for biosynthesizing UDP-glucose. In
S. cerevisiae, metabolic enzymes phosphoglucomutase (encoded by
PGM1 and PGM2) and UDP-glucose pyrophosphorylase (encoded
by UGP1) catalyze the formation of UDP-glucose branching from
glucose-6-phosphate (Supplementary Fig. 18a). Through chromo-
somally integrated expression of UGP1 with PGM1 or PGM2 in
strain I34, strains E07 and E08 were created. Additionally, to ensure
adequate UGTs activity, two multi-copy plasmids, harboring genes
PlUGT43 (pQC229) and GmUGT4 (pQC230) under the control of
GAL1p, were constructed and individually introduced into the high-
level producers of DEIN (strains I34, E07, and E08). In doing so, we
found the resultant strains E09 and E10, derived from the I34
background, to produce 45.2mg L−1 of PIN and 73.2mg L−1 of
DIN, respectively (Fig. 7c). Interestingly, compared with strain E10,
the PlUGT43-expressing strain E09 still accumulated a considerable
amount of DEIN (28.9 mg L−1, Fig. 7c). This discrepancy may be
attributed to the insufficient activity of PlUGT43, whose determined
kinetic parameters for DEIN (Kcat= 0.35 s−1, Km= 32.8 µM, and
Kcat/Km= 1.1 × 104M−1 s−1)71 show to be considerably less
optimal compared to GmUGT4 (Kcat= 5.89 s−1, Km= 20.3 µM,
and Kcat/Km= 2.91 × 105M−1 s−1)74. Furthermore, the conversion
of GEIN to 25.9 mg L−1 of C-glycoside genistein 8-C-glucoside
(G8G) and 26.5 mg L−1 of O-glycoside genistin (GIN) was
observed for strains E09 and E10 (Supplementary Fig. 18b and
c), respectively, since the selected UGTs exhibit comparable
glycosyltransferase activity towards GEIN71,74. Moreover, the
overexpression of UDP-glucose-forming genes resulted in
full consumption of DEIN and enhanced PIN production to
72.8 mg L−1 in E07-derived strain E11 and 65.4 mg L−1 in E08-
derived strain E12, representing a 61% and 45% increase
respectively compared with strain E09 (Fig. 7c). On the other
hand, such modifications resulted in no significant increase in
the production of DIN (Fig. 7c) and byproduct glucosides
(Supplementary Fig. 18b and c), reflecting a shortage of
precursor isoflavones. Similarly, we analyzed the growth-
inhibitory effects of the two glucosides on strain IMX581.
Compared with their aglycon DEIN, an increased level of PIN
(500 mg L−1) and DIN (250 mg L−1) can be tolerated by yeast
to retain normal cell growth (Supplementary Fig. 19); both
concentrations are much higher than the best titer achieved for
the two glucosides in our study. Specifically, supplementation of
DIN improved growth of yeast, which could result from the
uptake of DIN and then release of glucose catalyzed by native
glucosidases, such as the steryl-beta-glucosidase Egh1p75.
Discussion
Isoflavonoids play important roles in the plant defense system
and have many human health-related benefits. They, therefore,
represent promising candidates in the development and engi-
neering of agents for agricultural, nutraceutical, and pharma-
ceutical applications. Here we established a yeast-based de novo
production platform for the efficient production of the iso-
flavonoid carbon skeleton DEIN as well as the high-value glu-
cosides PIN and DIN. This was achieved by first identifying
functional biosynthetic enzymes to generate DEIN (screening
phase I), then by optimizing metabolic flux at enzyme and
pathway levels to further increase DEIN titer (reconstruction
phase II) and finally by introducing plant UGTs to convert DEIN
to corresponding glucosides (application phase III).
Gene duplication and diversification occur in the evolution of
plant secondary metabolism to tackle the changing environ-
ment, creating a rich variability and complexity of plant pro-
ducts as a result76. However, this functional divergence poses
an obstacle to identifying ideal candidate enzymes for recon-
structing heterologous biosynthetic pathways for plant meta-
bolite production. Most of the structural genes involved in
isoflavonoid pathways have been characterized25, and here we
exploited their genetic diversity, by performing a combinatorial
evaluation of biosynthetic genes from both leguminous and
non-leguminous plants, to enable DEIN production (Fig. 2b–d).
The P450s constitute the most versatile tailoring enzymes that
catalyze irreversible and often rate-limiting reactions in the
biosynthesis of plant-specialized products31. Though S. cerevi-
siae is generally identified as a superior host for the functional
expression of membrane-bound plant P450s over its prokar-
yotic counterparts, extra efforts are required to maximize their
catalytic efficiency. Two distinct P450s, the upstream C4H
hydroxylating cinnamic acid and the downstream 2-HIS med-
iating the migration of aryl moiety of LIG, are involved in the
biosynthesis of DEIN (Fig. 3a). While the activity of AtC4H has
been enhanced by co-expressing RP77 in our screening strains
providing excess precursor p-HCA (QL11 background), the
selected Ge2-HIS still exhibited sub-optimal performance in
converting LIG to DEIN (Supplementary Fig. 4). Starting with
evaluating plant CPRs and artificial RP surrogates, which could
impact the transfer of electrons required for P450 activity, we
therefore proceeded with the optimization of Ge2-HIS activity
by exploring other endogenous metabolic factors, including
heme metabolism, ER homeostasis, and NADPH generation.
These modifications increased DEIN titer to a level exceeding
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12 mg L−1 (Fig. 4b), accounting for a seven-fold improvement
compared with the parental strain C33.
Another challenge for isoflavonoid production lies in over-
coming the intrinsically low catalytic efficiency and/or selectivity
of enzymes participating in the biosynthesis of plant secondary
metabolites78. Gene amplification, by for example promoter
engineering, is one approach to enhance enzyme activity. Here,
implementation of dynamic expression control using inducible
GALps, which enable a higher level of gene transcription than
constitutive promoters79, boosted LIG production to 37.6 mg L−1
(Fig. 5b), a 284% increase relative to strain C09 having con-
stitutive expression of the pathway genes. Spatial micro-
compartmentalization via the formation of metabolons, which
are ordered complexes of enzymes participating in sequential
biosynthetic pathways, allows the effective formation of specia-
lized metabolites and has shown to reduce metabolic crosstalk in
plants80. To advance DEIN titers further, we therefore mimicked
this natural phenomenon by bringing enzymes into proximity,
using a linker-based fusion enzyme strategy, in turn greatly
improving the metabolic flux through the LIG pathway and
increasing its titer by 107% (Fig. 5b). Besides the AAA-derived p-
HCA, de novo isoflavonoid biosynthesis consumes malonyl-CoA,
whose formation is predominately invested in FAs synthesis in S.
cerevisiae61. By fine-tuning the expression of key enzymes
involved in FAs synthesis, we were able to redistribute the cellular
malonyl-CoA pool, resulting in a 20% further increase in DEIN
titer (Fig. 6f).
In conclusion, as a proof-of-concept study, a final DEIN titer of
85.4 mg L−1 was achieved using glucose as the sole carbon source
in shake flask cultivations (Fig. 6g). This production level is
comparable and, in some cases, higher than isoflavonoid levels
produced by previous studies, which have additionally been aided
with precursor feeding (Supplementary Table 2). Via further
expression of different glycosyltransferases, approximately
80 mg L−1 of C- or O-glycosylated bioactive compounds PIN or
DIN were produced (Fig. 7c), showing the application potential
of our platform strain. Moreover, our work sheds light on the
complete microbial biosynthesis of value-added isoflavonoids
such as DEIN-derived legume phytoalexins81 and may be
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Fig. 7 Production of DEIN-derived glucosides. a Schematic view of the engineered metabolic pathways for the biosynthesis of glucosides PIN and DIN
(pink box), and relevant byproducts (gray box). See Fig. 1 legend for gene details. b Characterization of metabolic enzymes responsible for glucoside
biosynthesis. Three copies of PlUGT43 and GmUGT4 under the control of constitutive promoters were integrated into the DEIN producer C28, resulting in
strains E03 and E06, respectively. Cells were grown in a defined minimal medium with 30 g L−1 glucose as the sole carbon source, and cultures were
sampled after 72 h of growth for LC-MS analysis. c Production profiles of PIN and DIN in DEIN hyper-producing strain I34 background with or without
increased UDP-glucose supply. Combined overexpression of genes PGM1/2 with UPG1 was implemented to enhance the generation of glycosyl group donor
UDP-glucose. See Fig. 1 legend for gene details. Cells were grown in a defined minimal medium with six tablets of FB as the sole carbon source and 10 g L−1
galactose as the inducer. Cultures were sampled after 90 h of growth for metabolite detection. Statistical analysis was performed by using Student’s t test
(two-tailed; two-sample unequal variance; *p < 0.05, **p < 0.01, ***p < 0.001). All data represent the mean of n= 3 biologically independent samples and
error bars show standard deviation. The source data underlying figure c are provided in a Source Data file.
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production of isoflavonoid derivatives. Additional improve-
ments on the catalytic efficiency and specificity of key iso-
flavonoid biosynthetic enzymes through protein engineering78,
directed pathway evolution facilitated by biosensor-mediated
high-throughput screening as well as engineering of extra-
cellular transport of isoflavonoids82,83, may further optimize the
phenotypes of our platform strains, including higher titer/pro-
ductivity and reduction/elimination of byproducts, to meet
industrial-scale production requirements in the future. Finally,
the multi-faceted framework we herein present also offers the
potential to be applied for engineering the biosynthetic path-
ways in other microbial hosts as well, for the production of
complex natural products.
Methods
Strains, plasmids, and reagents. Escherichia coli DH5α strain was used for the
construction and amplification of plasmids. All plasmids and S. cerevisiae strains
used in this study are listed in Supplementary Table 3 and Supplementary Data 1,
respectively. SapphireAmp® Fast PCR Master Mix and PrimeStar DNA polymerase
were purchased from TaKaRa Bio. High-fidelity Phusion DNA polymerase and
Gibson assembly kit were purchased from New England Biolabs. Plasmid mini-
prep, and DNA gel purification kits, and restriction enzymes were purchased from
ThermoFisher Scientific. All codon-optimized plant and bacterial genes were
chemically synthesized by GenScript and are listed in Supplementary Data 2. All
primers (Supplementary Data 3) and chemicals (including analytical standards)
were purchased from Sigma-Aldrich.
Strain cultivation. YPD medium, consisting of 20 g L−1 peptone (Difco), 10 g L−1
yeast extract (Merck Millipore), and 30 g L−1 glucose (VWR), was used for
routine yeast cultivation and preparation of competent cells. Synthetic complete
medium without uracil (SC-URA), consisting of 6.7 g L−1 yeast nitrogen base
(YNB) without amino acids (Formedium), 0.77 g L−1 complete supplement mix-
ture without uracil (CSM-URA, Formedium), 20 g L-1 glucose (VWR) and 20 g L−1
agar (Merck Millipore), was used for selection of yeast transformants harboring the
URA3 marker. To drop out the URA3 marker, yeast cultures were selected against
on SC with 5-fluoroorotic acid (SC+ 5-FOA) plates, containing 6.7 g L−1 YNB,
0.77 g L−1 complete supplement mixture and 0.8 g L−1 5-FOA.
Shake flask batch fermentations for the production of isoflavonoid compounds
were carried out in a defined minimal medium ((7.5 g L−1 (NH4)2SO4, 14.4 g L−1
KH2PO4, 0.5 g L−1 MgSO4 ∙ 7H2O, pH 6.0), 30 g L−1 glucose, 2 mL L−1 trace metal
(3.0 g L−1 FeSO4 ∙ 7H2O, 4.5 g L−1 ZnSO4 ∙ 7H2O, 4.5 g L−1 CaCl2 ∙ 2H2O, 0.84 g L−1
MnCl2 ∙ 2H2O, 0.3 g L−1 CoCl2 ∙ 6H2O, 0.3 g L−1 CuSO4 ∙ 5H2O, 0.4 g L−1
Na2MoO4 ∙ 2H2O, 1.0 g L−1 H3BO3, 0.1 g L−1 KI and 19.0 g L−1 Na2EDTA ∙ 2H20)
and 1mL L−1 vitamin solutions (0.05 g L−1 D-Biotin, 1.0 g L−1 D-Pantothenic acid
hemicalcium salt, 1.0 g L−1 Thiamin-HCl, 1.0 g L−1 Pyridoxin-HCl, 1.0 g L−1
Nicotinic acid, 0.2 g L−1 4-aminobenzoic acid, 25.0 g L−1 myo-Inositol)84
supplemented with 60mg L−1 uracil and 1mM 5-aminolevulinic acid (5-ALA) if
required. Single colonies, with PCR-verified genetic modifications, were inoculated
into 14mL tubes with 1.5mL fresh minimal medium and incubated at 30 °C with
220 rpm agitation overnight. Precultures were then diluted and transferred to a
125mL non-baffled flask containing 15mL minimal medium at an initial optical
density measured at 600 nm (OD600) of 0.05 and cultivated at 220 rpm, 30 °C for an
additional 72 h. For mimicked fed-batch shake flask cultivations, six tablets of
FeedBeads60 (SMFB08001, Kuhner Shaker, Basel, Switzerland) were used as the sole
carbon source and cultivated for 90 h at 30 °C with 220 rpm agitation (corresponding
to 30 g L−1 glucose). To induce the transcription of genes under the control of GALps,
10 g L−1 galactose was added into the medium as the gratuitous inducer.
Analysis of the growth-inhibitory effect of DEIN and its glucosides on yeast was
performed using Growth Profiler 960 (EnzyScreen). Overnight precultures were
diluted and transferred to 96-well microplates containing 250 µL defined minimal
medium with the initial OD600 of 0.1. DEIN was added to the wells in final
concentrations of 25, 100 and 150 mg L−1. PIN was added in a final concentration
of 50, 500, 1000 and 2000 mg L−1. DIN was added in a final concentration of 25, 50
and 250 mg L−1. The cultures were grown at 30 °C with 250 rpm shaking, and the
OD600 was measured with an interval of 30 min.
Genetic manipulation. All constructed yeast strains were derived from the genetic
background S. cerevisiae CEN.PK113-5D-derivative IMX581 (MATa ura3-52
can1Δ::cas9-natNT2 TRP1 LEU2 HIS3)85. For gene overexpression, in-vitro-
assembled DNA constructs were integrated at target genomic loci by means of the
CRISPR/cas9 system. For the amplification of native promoters, genes, and ter-
minators, IMX581 genomic DNA served as the template. Plasmids or synthetic
fragments were utilized as the DNA template to amplify optimized heterologous
genes (Supplementary Table 3 and Supplementary Data 2). High-fidelity Phusion
DNA polymerase was used for routine DNA fragment amplifications, except Pri-
meSTAR HS polymerase was selected for in vitro fusion PCR for generating
integration constructs. Functional expression modules were generated according to
an overlapping extension PCR (OE-PCR) procedure86. All used integration cas-
settes are listed in Supplementary Data 4.
Specific chromosomal loci, enabling stable and high-level expression of
heterologous genes87, were selected as the recombination sites for integration of
gene overexpression constructs. Construction of strain C09 was used as an example
to show the CRISPR/cas9-mediated integration of in-vitro-assembled DNA
constructs. Fragment M1 was generated through assembling DNA parts XII-1 us,
CYC1t, At4CL1, TDH3p, CCW12p, GmCHR5, FBA1t and TPS1t. In detail, the
upstream homologous arm XII-1 us (P190/P191), terminators CYC1t (P25/P26),
FBA1t (P27/P29) and TPS1t (P30/P31), and promoters TDH3p (P1/P2) and
CCW12p (P4/P5) were amplified from IMX581 genomic DNA, respectively; and
coding regions of At4CL1 (P44/P48) and GmCHR5 (P62/P66) were amplified using
pCfB0854 and synthetic gene as the template, respectively. Fragment M14 was
assembled by fusing the DNA parts of FBA1t, TPS1t, GmCHS8, TEF1p, PGK1p,
GmCHI1B2, ADH1t, and XII-1 ds. Specifically, coding regions of GmCHS8 (P85/
P89) and GmCHI1B2 (P100/P104) were amplified from synthetic genes; promoters
TEF1p (P6/P7) and PGK1p (P8/P9), terminator ADH1t (P32/P33) and the
downstream homologous arm XII-1 ds (P192/P193) were amplified from IMX581
genomic DNA, respectively. Subsequently, equimolar amounts of purified
fragments M1 and M14 (100 ng kb−1) with XII-1 targeting gRNA vector pQC032
(~300 ng) were mixed and co-transformed into p-HCA-producing strain QL11
using the lithium acetate-mediated yeast transformation protocol85. The resulting
transformants were selected on SC-URA plates and colony PCR using
SapphireAmp® Fast PCR Master Mix was performed to identify correct integrants.
For gene deletion, 2 µg of a double-stranded DNA fragment consisting of two 50 bp
sequences homologous to the flanking sequences of target genes, serving as the
homologous repair of the genome double-strand break introduced by the cleavage
of Cas9 nuclease, were co-transformed with corresponding gRNA vectors.
Likewise, resulting transformants were selected on SC-URA plates and colony PCR
using SapphireAmp® Fast PCR Master Mix was performed to identify correct
deletants. To construct the fusion protein of adjacent metabolic enzymes, two types
of flexible linker GGGS (flexible) and VDEAAAKSGR (rigid) were evaluated. For
the construction of the FAS1 promoter-substitution strains, the native promoter
sequences of FAS1 (from −90 to 0 bp) were replaced by selected promoters in
Supplementary Table 1 using the CRISPR/cas9 system. Galactose-degrading genes
GAL7/10/1 were deleted to enable galactose as a gratuitous inducer for the
transcription of genes under the control of GAL promoters. A schematic overview
of all strain construction is shown in Supplementary Fig. 2.
To obtain specific guide RNAs for a selected gene/genomic locus, all potential
gRNAs were identified and ranked with CEN.PK113-7D genetic background using
the free and open CRISPRdirect tool (http://crispr.dbcls.jp/)88. All single and
double gRNA plasmids were constructed according to the Gibson assembly method
in which gRNA sequence-containing DNA parts were in vitro recombined with a
vector backbone85. Correct recombinant plasmids were then verified by
sequencing. To construct bidirectional promoter vector pQC223, a fragment
consisting of GAL1p-GAL10p (P16/P24) was amplified from IMX581 genomic
DNA, gel-purified and recombined with a Kpn I/Sac I-digested pSP-GM1 backbone
using Gibson assembly method. E. coli colony PCR was then performed to identify
correct recombinant plasmids which were further confirmed by sequencing.
Metabolite extraction and quantification. Isoflavonoids and aromatic metabo-
lite production were quantified by high-performance liquid chromatography
(HPLC)27. In detail, 0.5 mL of cell culture was mixed with an equal volume of
absolute ethanol (100% v/v), vortexed thoroughly and centrifuged at 13,000 × g
for 5 min. The supernatant was stored at −20 °C until HPLC analysis. Quanti-
fication of isoflavonoids and aromatics was performed on a Dionex Ultimate 3000
HPLC (ThermoFisher Scientific, Waltham, MA, USA) equipped with a Discovery
HS F5 15 cm × 4.6 mm column (particle size 5 µm, Sigma-Aldrich, St. Louis, MO,
USA) connected to a photodiode array (PDA) detector (250, 270, 290, 304 and
370 nm). The column was kept at 30 °C, and metabolites from 10 µL of super-
natants were separated. Samples were analyzed using a gradient method with two
solvents: water with 0.1% formic acid (A) and acetonitrile (B). For p-HCA, NAG,
GEIN, ISOLIG, LIG, DEIN, DIN, PIN, GIN, and G8G detection, a flow rate of
1.2 ml min−1 was used. The program started with 5% of solvent B (0–0.5 min),
after which its fraction was increased linearly from 5 to 60% (0.5–18.5 min), then
the fraction was maintained at 60% (18.5–19 min), after that the fraction was
decreased from 60 to 5% (19–19.5 min), finally, the fraction was maintained at 5%
(19.5–20 min). p-HCA was detected at 9.3 min (304 nm), NAG at 14.8 min
(290 nm), GEIN at 14.5 min (270 nm), ISOLIG at 16.3 min (370 nm), LIG at
12.8 min (270 nm), DEIN at 12.0 min (250 nm), DIN at 8.1 min (250 nm), PIN at
7.1 min (250 nm), GIN at 9.7 min (250 nm) and G8G at 8.7 min (250 nm).
Chromeleon was used for HPLC data collection. Compound identity was con-
firmed by comparing the UV absorbance spectra and retention times of the
samples with authentic standards. A six-point calibration curve, ranging from
6.25 mg L−1 to 200 mg L−1 (p-HCA), 3.125 mg L−1 to 100 mg L−1 (NAG), and
1.5625 mg L−1 to 50 mg L−1 (GEIN, ISOLIG, LIG, DEIN, DIN, PIN, GIN and
G8G), was generated for the quantification of these chemicals. The R2 coefficient
for the resulting calibration curve was 0.99. Quantitative analysis was carried out
using Microsoft Excel.
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The glucose release kinetic of the FeedBeads was determined in a minimal
medium without a carbon source. Briefly, six tablets of FeedBeads were placed in a
125 mL non-baffled flask containing 15 mL minimal medium and incubated at
30 °C with an agitation rate of 220 rpm. 50 µL cultures were removed from the flask
at multiple time points and centrifuged at 13,000 × g for 5 min. The supernatant
was then stored at −20 °C until further analysis. The concentration of glucose was
quantified by HPLC analysis on an Aminex HPX-87G column (Bio-Rad) on an
Ultimate 3000 HPLC with a refractive index detector. The column was eluted with
5 mM H2SO4 at a flow rate of 0.6 mLmin−1 at 45 °C for 35 min. Chromeleon was
used for HPLC data collection and Microsoft Excel for further quantitative analysis.
Identification of glycosylated products. Liquid chromatography-mass spectro-
metry (LC-MS) analysis was performed to verify the production of PIN and DIN
by engineered yeast cells. Specifically, strains C28, E03, and E06 were cultivated in
15 mL minimal medium with 30 g L−1 glucose for 72 h. For the LC-MS sample
preparation, 2 mL resultant cell culture was collected and freeze-dried in a Christ
Alpha 2-4LSC for 48 h. Then, 1 mL of absolute ethanol was added, vigorously
vortexed for 10 min, and centrifuged at 13,000 × g for 5 min. The supernatant was
collected, fully dried under vacuum, and resuspended with 200 μL absolute ethanol.
Ten microliters of each sample was injected and analyzed on an Agilent Infinity
1290 UHPLC connected to an Agilent 6520 high-resolution mass spectrometry. The
UHPLC used a Waters UPLC HSS T3 10 cm× 2.1mm column (particle size 1.8 µm).
The column temperature was set to 45 °C and the flow rate was 0.4mlmin−1 with a
solvent system containing 0.04% formic acid (solvent A) and methanol with 0.04%
formic acid (solvent B). The gradient started at 5% solvent B and ramped to 100%
solvent B over 6 min and held for 4.5min. The LC eluent was directed to the MS
equipped with a Dual electrospray ionization (ESI) source in a positive ionization
mode scanning from 50 to 1200m/z at 1.67 spectra s−1. The capillary voltage was set
at 3500 V. The source parameters were set with a gas temperature at 175 °C, gas flow
at 10 Lmin−1, and nebulizer at 45 psig. MS data were acquired with Agilent
MassHunter LC-MS Data Acquisition and analyzed using Masshunter Qualitative
analysis.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Data supporting the findings of this study are available within the article and
its Supplementary Information files. The GenBank (https://www.ncbi.nlm.nih.gov/
genbank/) accession numbers and codon-optimized nucleotide sequences of the genes
referenced in this study are provided in this paper. All other data that support the
findings of this study are available from the corresponding author upon request. All
plasmids and strains used in this study are available from the corresponding author
under a material transfer agreement. Source data are provided with this paper.
Received: 23 August 2021; Accepted: 30 September 2021;
References
1. Veitch, N. C. Isoflavonoids of the leguminosae. Nat. Prod. Rep. 30, 988–1027
(2013).
2. Dixon, R. A. & Steele, C. L. Flavonoids and isoflavonoids—a gold mine for
metabolic engineering. Trends Plant Sci. 4, 394–400 (1999).
3. Sharma, V. & Ramawat, K. G. In Natural Products (eds Ramawat, K. G. &
Mérillon, J.-M.) 1849−1865 (Springer-Verlag, Berlin Heidelberg, 2013).
4. Dixon, R. A. & Pasinetti, G. M. Flavonoids and isoflavonoids: from plant
biology to agriculture and neuroscience. Plant Physiol. 154, 453–457 (2010).
5. Blicharski, T. & Oniszczuk, A. Extraction methods for the isolation of
isoflavonoids from plant material. Open Chem. 15, 34–45 (2017).
6. Sajid, M., Stone, S. R. & Kaur, P. Recent advances in heterologous synthesis
paving way for future green-modular bioindustries: a review with special
reference to isoflavonoids. Front. Bioeng. Biotechnol. 9, 673270 (2021).
7. Zaheer, K. & Humayoun Akhtar, M. An updated review of dietary isoflavones:
nutrition, processing, bioavailability and impacts on human health. Crit. Rev.
Food Sci. Nutr. 57, 1280–1293 (2017).
8. Keasling, J. D. Manufacturing molecules through metabolic engineering.
Science 330, 1355–1358 (2010).
9. Lee, S. Y. et al. A comprehensive metabolic map for production of bio-based
chemicals. Nat. Catal. 2, 18–33 (2019).
10. Nielsen, J. & Keasling, J. D. Engineering cellular metabolism. Cell 164,
1185–1197 (2016).
11. Galanie, S., Thodey, K., Trenchard, I. J., Filsinger Interrante, M. & Smolke, C.
D. Complete biosynthesis of opioids in yeast. Science 349, 1095–1100 (2015).
12. Paddon, C. J. et al. High-level semi-synthetic production of the potent
antimalarial artemisinin. Nature 496, 528–532 (2013).
13. Li, M. J. et al. De novo production of resveratrol from glucose or ethanol by
engineered Saccharomyces cerevisiae. Metab. Eng. 32, 1–11 (2015).
14. Pyne, M. E. et al. A yeast platform for high-level synthesis of
tetrahydroisoquinoline alkaloids. Nat. Commun. 11, 3337 (2020).
15. Levisson, M. et al. Engineering de novo anthocyanin production in
Saccharomyces cerevisiae. Micro. Cell Fact. 17, 103 (2018).
16. Chemler, J. A., Lim, C. G., Daiss, J. L. & Koffas, M. A. A versatile microbial
system for biosynthesis of novel polyphenols with altered estrogen receptor
binding activity. Chem. Biol. 17, 392–401 (2010).
17. Kim, B. G. Biological synthesis of genistein in Escherichia coli. J. Microbiol.
Biotechnol. 30, 770–776 (2019).
18. Trantas, E., Panopoulos, N. & Ververidis, F. Metabolic engineering of the
complete pathway leading to heterologous biosynthesis of various
flavonoids and stilbenoids in Saccharomyces cerevisiae. Metab. Eng. 11,
355–366 (2009).
19. Kim, D. H., Kim, B. G., Jung, N. R. & Ahn, J. H. Production of genistein
from naringenin using Escherichia coli containing isoflavone synthase-
cytochrome P450 reductase fusion protein. J. Microbiol. Biotechnol. 19,
1612–1616 (2009).
20. Katsuyama, Y., Miyahisa, I., Funa, N. & Horinouchi, S. One-pot synthesis of
genistein from tyrosine by coincubation of genetically engineered Escherichia
coli and Saccharomyces cerevisiae cells. Appl. Microbiol. Biotechnol. 73,
1143–1149 (2007).
21. Leonard, E. & Koffas, M. A. Engineering of artificial plant cytochrome P450
enzymes for synthesis of isoflavones by Escherichia coli. Appl. Environ.
Microbiol. 73, 7246–7251 (2007).
22. Koirala, N., Pandey, R. P., Thang, D. V., Jung, H. J. & Sohng, J. K.
Glycosylation and subsequent malonylation of isoflavonoids in E. coli: strain
development, production and insights into future metabolic perspectives. J.
Ind. Microbiol. Biotechnol. 41, 1647–1658 (2014).
23. He, X. Z., Li, W. S., Blount, J. W. & Dixon, R. A. Regioselective synthesis of
plant (iso)flavone glycosides in Escherichia coli. Appl. Microbiol. Biotechnol.
80, 253–260 (2008).
24. Ferrer, J. L., Austin, M. B., Stewart, C. Jr & Noel, J. P. Structure and function of
enzymes involved in the biosynthesis of phenylpropanoids. Plant Physiol.
Biochem. 46, 356–370 (2008).
25. Du, H., Huang, Y. & Tang, Y. Genetic and metabolic engineering of
isoflavonoid biosynthesis. Appl. Microbiol. Biotechnol. 86, 1293–1312 (2010).
26. Dastmalchi, M. & Dhaubhadel, S. Soybean chalcone isomerase: evolution of
the fold, and the differential expression and localization of the gene family.
Planta 241, 507–523 (2015).
27. Liu, Q. et al. Rewiring carbon metabolism in yeast for high level production of
aromatic chemicals. Nat. Commun. 10, 4976 (2019).
28. Bomati, E. K., Austin, M. B., Bowman, M. E., Dixon, R. A. & Noel, J. P.
Structural elucidation of chalcone reductase and implications for
deoxychalcone biosynthesis. J. Biol. Chem. 280, 30496–30503 (2005).
29. Xiong, D. et al. Improving key enzyme activity in phenylpropanoid pathway
with a designed biosensor. Metab. Eng. 40, 115–123 (2017).
30. Hashim, M. F., Hakamatsuka, T., Ebizuka, Y. & Sankawa, U. Reaction
mechamism of oxidative rearrangement of flavanone in isoflavone
biosynthesis. FEBS Lett. 271, 219–222 (1990).
31. Shang, Y. & Huang, S. Engineering plant cytochrome P450s for
enhancedsynthesis of natural products: past achievements and future
perspectives. Plant Commun. 1, 100012 (2020).
32. Hannemann, F., Bichet, A., Ewen, K. M. & Bernhardt, R. Cytochrome P450
systems-biological variations of electron transport chains. Biochim. Biophys.
Acta 1770, 330–344 (2007).
33. Jensen, K. & Moller, B. L. Plant NADPH-cytochrome P450 oxidoreductases.
Phytochemistry 71, 132–141 (2010).
34. Ciaramella, A., Minerdi, D. & Gilardi, G. Catalytically self-sufficient
cytochromes P450 for green production of fine chemicals. Rendiconti Lincei
28, 169–181 (2016).
35. Narhi, L. O. & Fulco, A. J. Characterization of a catalytically self-sufficient
119,000-dalton cytochrome P-450 monooxygenase induced by barbiturates in
Bacillus megaterium. J. Biol. Chem. 261, 7160–7169 (1986).
36. Hunter, D. J. et al. Analysis of the domain properties of the novel cytochrome
P450 RhF. FEBS Lett. 579, 2215–2220 (2005).
37. Zhang, W. et al. New reactions and products resulting from alternative
interactions between the P450 enzyme and redox partners. J. Am. Chem. Soc.
136, 3640–3646 (2014).
38. Michener, J. K., Nielsen, J. & Smolke, C. D. Identification and treatment of
heme depletion attributed to overexpression of a lineage of evolved P450
monooxygenases. Proc. Natl Acad. Sci. USA 109, 19504–19509 (2012).
39. Hoffman, M., Gora, M. & Rytka, J. Identification of rate-limiting steps in yeast
heme biosynthesis. Biochem. Biophys. Res. Commun. 310, 1247–1253 (2003).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-26361-1 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:6085 | https://doi.org/10.1038/s41467-021-26361-1 | www.nature.com/naturecommunications 13
40. Zhang, T., Bu, P., Zeng, J. & Vancura, A. Increased heme synthesis in
yeast induces a metabolic switch from fermentation to respiration even
under conditions of glucose repression. J. Biol. Chem. 292, 16942–16954
(2017).
41. Savitskaya, J., Protzko, R. J., Li, F. Z., Arkin, A. P. & Dueber, J. E. Iterative
screening methodology enables isolation of strains with improved properties
for a FACS-based screen and increased L-DOPA production. Sci. Rep. 9, 5815
(2019).
42. Werck-Reichhart, D. & Feyereisen, R. Cytochromes P450: a success story.
Genome Biol. 1, REVIEWS3003 (2000).
43. Kim, J. E. et al. Tailoring the Saccharomyces cerevisiae endoplasmic reticulum
for functional assembly of terpene synthesis pathway. Metab. Eng. 56, 50–59
(2019).
44. Arendt, P. et al. An endoplasmic reticulum-engineered yeast platform for
overproduction of triterpenoids. Metab. Eng. 40, 165–175 (2017).
45. Liu, Y., Liu, Q., Krivoruchko, A., Khoomrung, S. & Nielsen, J. Engineering
yeast phospholipid metabolism for de novo oleoylethanolamide production.
Nat. Chem. Biol. 16, 197–205 (2020).
46. Adeyo, O. et al. The yeast lipin orthologue Pah1p is important for biogenesis
of lipid droplets. J. Cell Biol. 192, 1043–1055 (2011).
47. Carman, G. M. & Han, G. S. Regulation of phospholipid synthesis in the yeast
Saccharomyces cerevisiae. Annu. Rev. Biochem. 80, 859–883 (2011).
48. Kim, J. E., Jang, I. S., Sung, B. H., Kim, S. C. & Lee, J. Y. Rerouting of NADPH
synthetic pathways for increased protopanaxadiol production in
Saccharomyces cerevisiae. Sci. Rep. 8, 15820 (2018).
49. Cadiere, A., Galeote, V. & Dequin, S. The Saccharomyces cerevisiae zinc factor
protein Stb5p is required as a basal regulator of the pentose phosphate
pathway. FEMS Yeast Res. 10, 819–827 (2010).
50. Spaans, S. K., Weusthuis, R. A., van der Oost, J. & Kengen, S. W.
NADPH-generating systems in bacteria and archaea. Front. Microbiol. 6,
742 (2015).
51. Shi, F., Kawai, S., Mori, S., Kono, E. & Murata, K. Identification of ATP-
NADH kinase isozymes and their contribution to supply of NADP(H) in
Saccharomyces cerevisiae. FEBS J. 272, 3337–3349 (2005).
52. Shi, A., Zhu, X., Lu, J., Zhang, X. & Ma, Y. Activating transhydrogenase and
NAD kinase in combination for improving isobutanol production. Metab.
Eng. 16, 1–10 (2013).
53. Egriboz, O. et al. Self-association of the Gal4 inhibitor protein Gal80 is
impaired by Gal3: evidence for a new mechanism in the GAL gene switch.
Mol. Cell Biol. 33, 3667–3674 (2013).
54. Siu, K. H. et al. Synthetic scaffolds for pathway enhancement. Curr. Opin.
Biotechnol. 36, 98–106 (2015).
55. Albertsen, L. et al. Diversion of flux toward sesquiterpene production in
Saccharomyces cerevisiae by fusion of host and heterologous enzymes. Appl.
Environ. Microbiol. 77, 1033–1040 (2011).
56. Lee, D., Lloyd, N. D., Pretorius, I. S. & Borneman, A. R. Heterologous
production of raspberry ketone in the wine yeast Saccharomyces cerevisiae via
pathway engineering and synthetic enzyme fusion. Micro. Cell Fact. 15, 49
(2016).
57. Kochs, G. & Grisebach, H. Enzymic synthesis of isoflavones. Eur. J. Biochem.
155, 311–318 (1986).
58. Sawada, Y. & Ayabe, S. Multiple mutagenesis of P450 isoflavonoid synthase
reveals a key active-site residue. Biochem. Biophys. Res. Commun. 330,
907–913 (2005).
59. Gombert, A. K., Moreira dos Santos, M., Christensen, B. & Nielsen, J. Network
identification and flux quantification in the central metabolism of
Saccharomyces cerevisiae under different conditions of glucose repression. J.
Bacteriol. 183, 1441–1451 (2001).
60. Jeude, M. et al. Fed-batch mode in shake flasks by slow-release technique.
Biotechnol. Bioeng. 95, 433–445 (2006).
61. Tehlivets, O., Scheuringer, K. & Kohlwein, S. D. Fatty acid synthesis and
elongation in yeast. Biochim. Biophys. Acta 1771, 255–270 (2007).
62. Wenz, P., Schwank, S., Hoja, U. & Schuller, H. J. A downstream regulatory
element located within the coding sequence mediates autoregulated expression
of the yeast fatty acid synthase gene FAS2 by the FAS1 gene product. Nucleic
Acids Res. 29, 4625–4632 (2001).
63. Keren, L. et al. Promoters maintain their relative activity levels under different
growth conditions. Mol. Syst. Biol. 9, 701 (2013).
64. Blank, T. E., Woods, M. P., Lebo, C. M., Xin, P. & Hopper, J. E. Novel Gal3
proteins showing altered Gal80p binding cause constitutive transcription of
Gal4p-activated genes in Saccharomyces cerevisiae. Mol. Cell Biol. 17,
2566–2575 (1997).
65. Ryo, S. et al. Positive feedback genetic circuit incorporating a constitutively
active mutant Gal3 into yeast GAL induction system. ACS Synth. Biol. 6,
928–935 (2017).
66. Wittschieben, B. Ø. et al. A novel histone acetyltransferase is an integral
subunit of elongating RNA polymerase II holoenzyme. Mol. Cell 4, 123–128
(1999).
67. Muratani, M., Kung, C., Shokat, K. M. & Tansey, W. P. The F box protein
Dsg1/Mdm30 is a transcriptional coactivator that stimulates Gal4 turnover
and cotranscriptional mRNA processing. Cell 120, 887–899 (2005).
68. Le Roy, J., Huss, B., Creach, A., Hawkins, S. & Neutelings, G. Glycosylation is
a major regulator of phenylpropanoid availability and biological activity in
plants. Front. Plant Sci. 7, 735 (2016).
69. Noguchi, A. et al. A UDP-glucose:isoflavone 7-O-glucosyltransferase from the
roots of soybean (glycine max) seedlings. Purification, gene cloning,
phylogenetics, and an implication for an alternative strategy of enzyme
catalysis. J. Biol. Chem. 282, 23581–23590 (2007).
70. Gul, K., Singh, A. K. & Jabeen, R. Nutraceuticals and functional foods: the
foods for the future world. Crit. Rev. Food Sci. Nutr. 56, 2617–2627 (2016).
71. Wang, X., Li, C., Zhou, C., Li, J. & Zhang, Y. Molecular characterization of the
C-glucosylation for puerarin biosynthesis in Pueraria lobata. Plant J. 90,
535–546 (2017).
72. Zhou, Y. X., Zhang, H. & Peng, C. Puerarin: a review of pharmacological
effects. Phytother. Res. 28, 961–975 (2014).
73. Veitch, N. C. & Grayer, R. J. Flavonoids and their glycosides, including
anthocyanins. Nat. Prod. Rep. 28, 1626–1695 (2011).
74. Funaki, A. et al. Identification of a highly specific isoflavone 7-O-
glucosyltransferase in the soybean (Glycine max (L.) Merr.). Plant Cell Physiol.
56, 1512–1520 (2015).
75. Wang, H. et al. Engineering Saccharomyces cerevisiae with the deletion of
endogenous glucosidases for the production of flavonoid glucosides. Micro.
Cell Fact. 15, 134 (2016).
76. Hartmann, T. From waste products to ecochemicals: fifty years research of
plant secondary metabolism. Phytochemistry 68, 2831–2846 (2007).
77. Li, M., Schneider, K., Kristensen, M., Borodina, I. & Nielsen, J. Engineering yeast
for high-level production of stilbenoid antioxidants. Sci. Rep. 6, 36827 (2016).
78. Bar-Even, A. & Salah Tawfik, D. Engineering specialized metabolic pathways-
is there a room for enzyme improvements? Curr. Opin. Biotechnol. 24,
310–319 (2013).
79. Blazeck, J., Garg, R., Reed, B. & Alper, H. S. Controlling promoter strength
and regulation in Saccharomyces cerevisiae using synthetic hybrid promoters.
Biotechnol. Bioeng. 109, 2884–2895 (2012).
80. Jorgensen, K. et al. Metabolon formation and metabolic channeling in the
biosynthesis of plant natural products. Curr. Opin. Plant Biol. 8, 280–291 (2005).
81. Ahmed, S. & Kovinich, N. Regulation of phytoalexin biosynthesis for
agriculture and human health. Phytochem. Rev. 20, 483–505 (2021).
82. Liu, Q., Liu, Y., Chen, Y. & Nielsen, J. Current state of aromatics production
using yeast: achievements and challenges. Curr. Opin. Biotechnol. 65, 65–74
(2020).
83. Wang, G. et al. Transportome-wide engineering of Saccharomyces cerevisiae.
Metab. Eng. 64, 52–63 (2021).
84. Verduyn, C., Postma, E., Scheffers, W. A. & Van Dijken, J. P. Effect of benzoic
acid on metabolic fluxes in yeasts: a continuous-culture study on the
regulation of respiration and alcoholic fermentation. Yeast 8, 501–517 (1992).
85. Mans, R. et al. CRISPR/Cas9: a molecular Swiss army knife for simultaneous
introduction of multiple genetic modifications in Saccharomyces cerevisiae.
FEMS Yeast Rev. 15, fov004 (2015).
86. Zhou, Y. J. J. et al. Modular pathway engineering of diterpenoid synthases and
the mevalonic acid pathway for miltiradiene production. J. Am. Chem. Soc.
134, 3234–3241 (2012).
87. Mikkelsen, M. D. et al. Microbial production of indolylglucosinolate through
engineering of a multi-gene pathway in a versatile yeast expression platform.
Metab. Eng. 14, 104–111 (2012).
88. Naito, Y., Hino, K., Bono, H. & Ui-Tei, K. CRISPRdirect: software for
designing CRISPR/Cas guide RNA with reduced off-target sites.
Bioinformatics 31, 1120–1123 (2015).
Acknowledgements
We would like to thank Dr. Kate Campbell for critically reading the manuscript, and
Dr. Xiaowei Li and Dr. Yating Hu for assistance with Growth Profiler experiment. This
work received financial support from the Novo Nordisk Foundation (NNF10CC1016517
and NNF18OC0034844), the European Union’s Horizon 2020 research and innovation
program under grant agreement no. 814650, and the Knut and Alice Wallenberg
Foundation.
Author contributions
Q.L., Y.L. and J.N. conceived the study; Q.L. and Y.L. designed and performed all the
experiments and analyzed the data; G.L. and O.S. assisted with experimental perfor-
mance; Y.C. assisted with experimental design; Q.L., Y.L. and J.N. wrote the manuscript.
All authors discussed the data and made comments on the manuscript.
Funding
Open access funding provided by Chalmers University of Technology.
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-26361-1
14 NATURE COMMUNICATIONS |         (2021) 12:6085 | https://doi.org/10.1038/s41467-021-26361-1 | www.nature.com/naturecommunications
Competing interests
J.N. is a shareholder in Biopetrolia AB and Chrysea, Inc. All other authors declare no
competing interests.
Additional information
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41467-021-26361-1.
Correspondence and requests for materials should be addressed to Jens Nielsen.
Peer review information Nature Communications thanks Mauricio Rostagno for their
contribution to the peer review of this work.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2021
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-26361-1 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:6085 | https://doi.org/10.1038/s41467-021-26361-1 | www.nature.com/naturecommunications 15
